Device Trial Radar · NCT06735833
MMA Embolization for Refractory Chronic Migraine
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
31
Actual
Start
Apr 23, 2025
Primary completion
Dec 25, 2026
Study completion Jul 31, 2029
Sponsor
- Lead sponsor
- Cerenovus, Part of DePuy Synthes Products, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Dec 16, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Device feasibility
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, multi-center, feasibility study to investigate safety and effectiveness of TRUFILL n-BCA liquid embolic system in bilateral middle meningeal artery (MMA) embolization for the treatment of refractory chronic migraine.
Conditions
- Migraine Disorders
Interventions
Middle Meningeal Artery embolizationDevice
Bilateral middle meningeal artery embolization using TRUFILL n-BCA liquid embolic system
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline, in number of migraine daysTime frame: over 28 days post study intervention
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
John Muir Physician Network Clin. Research Center
Walnut Creek, California
Hartford Hospital
Hartford, Connecticut
University of Buffalo Medical Center
Buffalo, New York
5 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.